DTIL – Precision BioSciences, Inc.
Precision BioSciences, Inc.DTIL
$5.68Name : Precision BioSciences, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $66,950,108.00
EPSttm : -10.15
Precision BioSciences, Inc.
$5.68
0.18%$0.01Float Short %
12.23
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
1.21
EPS Last/This Y
-8.95
EPS This/Next Y
2.87
Price
5.68
Target Price
36.33
Analyst Recom
1
Performance Q
20.08
Relative Volume
0.52
Beta
1.75
Ticker: DTIL
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | DTIL | 4.96 | N/A | N/A | 0 |
| 2025-09-09 | DTIL | 5.14 | N/A | N/A | 0 |
| 2025-09-10 | DTIL | 4.98 | N/A | N/A | 0 |
| 2025-09-11 | DTIL | 5.02 | N/A | N/A | 0 |
| 2025-09-12 | DTIL | 4.62 | N/A | N/A | 0 |
| 2025-09-15 | DTIL | 4.5 | N/A | N/A | 0 |
| 2025-09-16 | DTIL | 4.64 | N/A | N/A | 0 |
| 2025-09-17 | DTIL | 4.53 | N/A | N/A | N/A |
| 2025-09-18 | DTIL | 4.95 | N/A | N/A | 0 |
| 2025-09-22 | DTIL | 4.9 | N/A | N/A | 0 |
| 2025-09-23 | DTIL | 4.92 | N/A | N/A | 0 |
| 2025-09-24 | DTIL | 5.05 | N/A | N/A | 0 |
| 2025-09-25 | DTIL | 4.97 | N/A | N/A | 0 |
| 2025-09-26 | DTIL | 5.05 | N/A | N/A | 0 |
| 2025-09-29 | DTIL | 5.11 | N/A | N/A | 0 |
| 2025-09-30 | DTIL | 5.49 | N/A | N/A | 0 |
| 2025-10-01 | DTIL | 5.46 | N/A | N/A | 0 |
| 2025-10-02 | DTIL | 5.38 | N/A | N/A | 0 |
| 2025-10-03 | DTIL | 5.41 | N/A | N/A | 0 |
| 2025-10-06 | DTIL | 5.68 | N/A | N/A | 0 |
| 2025-10-07 | DTIL | 5.66 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | DTIL | 4.97 | 1.8 | - | -8.17 |
| 2025-09-09 | DTIL | 5.12 | 1.8 | - | -8.17 |
| 2025-09-10 | DTIL | 5.02 | 1.8 | - | -8.17 |
| 2025-09-11 | DTIL | 5.00 | 1.8 | - | -8.17 |
| 2025-09-12 | DTIL | 4.64 | 1.8 | - | -8.17 |
| 2025-09-15 | DTIL | 4.51 | 1.8 | - | -8.17 |
| 2025-09-16 | DTIL | 4.67 | 1.8 | - | -8.17 |
| 2025-09-17 | DTIL | 4.56 | 1.8 | - | -8.17 |
| 2025-09-18 | DTIL | 4.92 | 1.8 | - | -8.17 |
| 2025-09-19 | DTIL | 4.74 | 1.8 | - | -8.17 |
| 2025-09-22 | DTIL | 4.86 | 1.8 | - | -8.17 |
| 2025-09-23 | DTIL | 4.90 | 1.8 | - | -8.17 |
| 2025-09-24 | DTIL | 5.07 | 1.8 | - | -8.17 |
| 2025-09-25 | DTIL | 4.93 | 1.8 | - | -8.17 |
| 2025-09-26 | DTIL | 5.06 | 1.8 | - | -8.17 |
| 2025-09-29 | DTIL | 5.09 | 1.8 | - | -8.17 |
| 2025-09-30 | DTIL | 5.53 | 1.8 | - | -7.90 |
| 2025-10-01 | DTIL | 5.47 | 1.8 | - | -7.90 |
| 2025-10-02 | DTIL | 5.43 | 1.8 | - | -7.90 |
| 2025-10-03 | DTIL | 5.41 | 1.8 | - | -7.90 |
| 2025-10-06 | DTIL | 5.66 | 1.8 | - | -7.90 |
| 2025-10-07 | DTIL | 5.68 | 1.8 | - | -7.90 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | DTIL | 0.03 | 12.31 | 12.88 |
| 2025-09-09 | DTIL | 0.03 | 12.31 | 12.88 |
| 2025-09-10 | DTIL | 0.03 | 12.31 | 12.88 |
| 2025-09-11 | DTIL | 0.03 | 12.31 | 12.03 |
| 2025-09-12 | DTIL | 0.03 | 12.31 | 12.03 |
| 2025-09-15 | DTIL | 0.03 | 12.30 | 12.03 |
| 2025-09-16 | DTIL | 0.03 | 12.30 | 12.03 |
| 2025-09-17 | DTIL | 0.03 | 12.30 | 12.03 |
| 2025-09-18 | DTIL | 0.03 | 12.30 | 12.03 |
| 2025-09-19 | DTIL | 0.03 | 12.30 | 12.03 |
| 2025-09-22 | DTIL | 0.03 | 12.30 | 12.03 |
| 2025-09-23 | DTIL | 0.03 | 12.30 | 12.03 |
| 2025-09-24 | DTIL | 0.09 | 12.30 | 12.03 |
| 2025-09-25 | DTIL | 0.09 | 12.30 | 12.23 |
| 2025-09-26 | DTIL | 0.13 | 12.30 | 12.23 |
| 2025-09-29 | DTIL | -0.29 | 12.30 | 12.23 |
| 2025-09-30 | DTIL | -0.17 | 12.30 | 12.23 |
| 2025-10-01 | DTIL | -0.17 | 12.30 | 12.23 |
| 2025-10-02 | DTIL | -0.17 | 12.30 | 12.23 |
| 2025-10-03 | DTIL | -0.17 | 12.30 | 12.23 |
| 2025-10-06 | DTIL | -0.17 | 6.15 | 12.23 |
| 2025-10-07 | DTIL | -0.17 | 6.15 | 12.23 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-2.13
Avg. EPS Est. Current Quarter
-2.21
Avg. EPS Est. Next Quarter
-0.92
Insider Transactions
-0.17
Institutional Transactions
6.15
Beta
1.75
Average Sales Estimate Current Quarter
5
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
14
Growth Score
32
Sentiment Score
43
Actual DrawDown %
98.9
Max Drawdown 5-Year %
-99.2
Target Price
36.33
P/E
Forward P/E
PEG
P/S
53.13
P/B
1.94
P/Free Cash Flow
EPS
-8.81
Average EPS Est. Cur. Y
-7.9
EPS Next Y. (Est.)
-5.03
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-6205.79
Relative Volume
0.52
Return on Equity vs Sector %
-255
Return on Equity vs Industry %
-241.3
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.27
EBIT Estimation
Precision BioSciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 102
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
stock quote shares DTIL – Precision BioSciences, Inc. Stock Price stock today
news today DTIL – Precision BioSciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DTIL – Precision BioSciences, Inc. yahoo finance google finance
stock history DTIL – Precision BioSciences, Inc. invest stock market
stock prices DTIL premarket after hours
ticker DTIL fair value insiders trading